In clinical trials it is being investigated for obesity and overweight with weight-related conditions, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease
On 07/01/2024 the Tema Obesity & Cardiometabolic ETF was renamed Tema GLP-1, Obesity & Cardiometabolic ETF
For bodybuilders who have struggled with adherence during cuts, this alone justifies the compound
Any website advertising "branded," "compounded," or "research" retatrutide for direct purchase should be treated as a serious warning sign
How long before I notice effects from adding MOTS-C to my Retatrutide protocol
TRIUMPH-4 also tested a 9mg dose, and additional trials are evaluating a 4mg maintenance dose